INmune Bio (INMB)
(Real Time Quote from BATS)
$6.15 USD
0.00 (0.00%)
Updated Sep 5, 2024 02:18 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
INmune Bio, Inc. [INMB]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for INMB 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Memory-Like NK Cells Seen in First High-Risk MDS Patient Taking INKmune
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Phase 2 AD Trial Defined, First INKmune Dosing, Cash Into Late 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Phase 1 AD Trial Progressing Well, Several Trials to Start in 2H21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -COVID-19 Therapeutics Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Phase 1 AD Trial Progressing Well, Also Focusing On TRD & COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
XPro Lowers Neuroinflammation & Neurodegeneration, Phase 2 Start in 2H21
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
INmune Bio?s Alzheimer?s Candidate Is a Potential Best-In-Class Drug
Provider: Quantum Research Group, LLC
Analyst: Research Department
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Oncology Franchise on the Back Burner; Lower $15 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: INmune Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: Focused on AD, COVID-19 - TRD Trials Until Pandemic Allows for More
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J